Functional vs. Psilocybin Mushrooms: A Guide to Investing

As psychedelics move into mainstream media, the attention on substances such as psilocybin and MDMA grows. Chances are good that you’ve heard of psilocybin mushrooms, but did you know that an entirely different category of mushrooms exists, nonpsychedelics that are called functional mushrooms. Examples of these mushrooms include reishi, chaga and lion’s mane.

These two growing markets can both be considered as potential investment opportunities. Below, we look at their differences and examine the potential for growth and profit for investors.

Wellness space or media spotlight: Which is better?

Magic mushrooms are hallucinogenic mushrooms that have the psychoactive component psilocybin. The mushrooms are said to induce hallucinations or feelings of euphoria in consumers. These mushrooms were discovered in the 1960s by Western science. However, research on the mushroom ground to a halt when the war on drugs begun a decade later. The mushrooms are now being studied across the globe again, with researchers hoping to learn more about the various health benefits they possess.

These mushrooms are being used in various studies to treat conditions such as PTSD and anxiety as well as depression. The state of Oregon and Washington, DC, approving a vote for a new status for these mushrooms coupled with their low addictive potential may pave the way for their decriminalization and eventual legalization.

On the other hand, functional mushrooms are recognized as healthy fungi by many ancient traditions and cultures. These fungi provide the body with important nutrients while also offering support to the natural systems of the body. This makes these specific mushrooms easily obtainable. Their use is also not prohibited or illegal, which has allowed them to be used in many wellness commodities. The functional mushrooms’ ability to help an individual’s body adapt to harmful environmental conditions such as stress cement their importance in the wellness space.

Magic mushrooms aren’t legal…yet

Psychedelic mushrooms and the psilocybin it produces aren’t legal in many parts of the world. This means that currently they cannot be produced or sold on a commercial scale. In areas where the mushrooms have been decriminalized, the only companies that can benefit from them are those that conduct therapeutic or medical research. This means that psilocybin sellers and manufacturers will have to wait for the market to grow, which will likely be after the psychedelic substance has been legalized.

In contrast, nothing is preventing companies that are selling functional mushrooms from establishing their markets and seeking growth and development.

Magic mushrooms are currently in the spotlight, attracting a lot of attention, which isn’t necessarily bad. However, the market is far from established, and much is still unknown about the psychedelic mushrooms. In comparison, functional mushroom markets have the potential for bigger growth and have few barriers that may hinder them from successful growth.

Potential investors should research the matter with an eye on possibly taking advantage of the new wave of wellness. Some entities, such as Pure Extracts Technologies Inc. (CSE: PULL), are involved in developing both functional and psychedelic mushroom products.

NOTE TO INVESTORS: The latest news and updates relating to Pure Extracts Technologies Corp. (CSE: PULL) are available in the company’s newsroom at

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.


Select A Month

PsychedelicNewsWire Currently Accepts



Bitcoin Cash

Bitcoin Cash

Doge Coin






USD Coin

USD Coin

Contact us: 415.949.5050